GlassScriptPhysician profile
Alison A Carpenter
NPI 1356851901
$4,897.61
in general payments reported to CMS, 2019-2025
22 companies · $1,526 in 2025
The $1,526 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $144 · 2022: $249 · 2023: $1,834 · 2024: $1,144 · 2025: $1,526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,225 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,225.49 |
| Education | $278.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,148.63 | 2021-2025 | |
| Genzyme Corporation | $656.71 | 2022-2025 | |
| Janssen Biotech, INC. | $506.69 | 2022-2024 | Tremfya, Simponi, Simponi Aria |
| Dermavant Sciences, INC. | $340.17 | 2023-2024 | Vtama |
| Lilly USA, LLC | $337.05 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $306.46 | 2023-2025 | Ilumya, Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $219.39 | 2023-2025 | |
| Ucb, INC. | $208.58 | 2023-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $203.16 | 2023-2025 | Sotyktu |
| Leo Pharma INC. | $192.53 | 2021-2024 | Adbry |
| Galderma Laboratories, L.P. | $171.05 | 2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $99.81 | 2023 | Libtayo, Dupixent |
| Organon LLC | $79.53 | 2024-2025 | Hadlima |
| Incyte Corporation | $78.27 | 2023-2025 | Opzelura |
| Strata Skin Sciences, INC. | $67.95 | 2023-2025 | Xtrac |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $67.33 | 2024 | Sotyktu |
| Fresenius Kabi USA, LLC | $58.89 | 2023-2024 | Idacio |
| Pfizer INC. | $43.72 | 2022-2023 | |
| Botanix Sb INC | $40.53 | 2025 | Sofdra |
| Amgen INC. | $29.05 | 2025 | Otezla |
| Sandoz INC. | $23.26 | 2024 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2023 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.